Biologics & Biosimilars

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

May 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

May 7, 2019 • By Michele B. Kaufman, PharmD, BCGP

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

April 25, 2019 • By Megan Brooks

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

April 22, 2019 • By Will Boggs MD

Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis

April 15, 2019 • By Michele B. Kaufman, PharmD, BCGP

Mirikizumab Promising for Plaque Psoriasis

April 10, 2019 • By Michele B. Kaufman, PharmD, BCGP

Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

April 3, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Guselkumab Injector

March 20, 2019 • By Michele B. Kaufman, PharmD, BCGP

Biosimilars: How Do They Affect Patient Care & Safety?

March 19, 2019 • By Lara C. Pullen, PhD

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

February 17, 2019 • By Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD